{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Number of participants with dose-limiting toxicities as a measure of safety profile to determine recommended dose of ibrutinib","groups":[{"description":"Subjects receive daily dose of 420 mg of Ibrutinib capsules for dose level 1","id":"OG000","title":"Phase 1b: Dose Level 1"},{"description":"Subjects receive daily dose of 420 mg of Ibrutinib capsules","id":"OG001","title":"Phase 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Endpoint only includes Phase 1 data.","reportingStatus":"POSTED","timeFrame":"28 treatment days after last subject enrolled in Phase 1 dose level(s).","title":"Phase 1b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD.","type":"PRIMARY","unitOfMeasure":"Participants"}